Somatostatin Analogs (SSA) in Patients with Symptomatic Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)

#2754

Introduction: DIPNECH is characterized by a proliferation of pulmonary neuroendocrine cells and multifocal neuroendocrine tumorlets and/or tumors. Although usually indolent, DIPNECH can cause chronic cough and dyspnea. There is very limited information on treatment.

Aim(s): To assess changes in symptoms and pulmonary function tests (PFTs) in response to somatostatin analog (SSA) therapy.

Materials and methods: Patients with either clinical or pathological diagnosis of DIPNECH and chronic respiratory symptoms received SSA therapy at the Moffitt Cancer Center, Hadassah Medical Center, and Mayo Clinic. Chart reviews were conducted to assess changes in symptoms and pulmonary function tests.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, Strosberg J, Halfdanarson T, Oleinikov K, Gross D,

Keywords: DIPNECH, Somatostatin analogs, Octreotide, Lanreotide,